231 related articles for article (PubMed ID: 26586647)
21. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment.
Abate D; Tedla Y; Meressa D; Ameni G
Int J Tuberc Lung Dis; 2014 Aug; 18(8):946-51. PubMed ID: 25199009
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis.
Hsu HL; Bai KJ; Chiang YC; Lin SJ; Yu MC
J Formos Med Assoc; 2010 Dec; 109(12):923-7. PubMed ID: 21195892
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.
Garcia-Contreras L; Padilla-Carlin DJ; Sung J; VerBerkmoes J; Muttil P; Elbert K; Peloquin C; Edwards D; Hickey A
J Pharm Sci; 2017 Jan; 106(1):331-337. PubMed ID: 27842973
[TBL] [Abstract][Full Text] [Related]
24. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy.
Fajardo TT; Guinto RS; Cellona RV; Abalos RM; Dela Cruz EC; Gelber RH
Am J Trop Med Hyg; 2006 Mar; 74(3):457-61. PubMed ID: 16525107
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Development of Inhalable d-Cycloserine and Ethionamide To Overcome Pharmacokinetic Interaction and Enhance Efficacy against
Ranjan R; Srivastava A; Bharti R; Roy T; Verma S; Ray L; Misra A
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962335
[TBL] [Abstract][Full Text] [Related]
26. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457
[TBL] [Abstract][Full Text] [Related]
27. Abnormal thyroid function tests in children on ethionamide treatment.
Thee S; Zöllner EW; Willemse M; Hesseling AC; Magdorf K; Schaaf HS
Int J Tuberc Lung Dis; 2011 Sep; 15(9):1191-3, i. PubMed ID: 21943844
[TBL] [Abstract][Full Text] [Related]
28. The Value of the
Song Y; Wang G; Li Q; Liu R; Ma L; Li Q; Gao M
Infect Drug Resist; 2021; 14():329-334. PubMed ID: 33551644
[TBL] [Abstract][Full Text] [Related]
29. Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide.
Zhang HN; Xu ZW; Jiang HW; Wu FL; He X; Liu Y; Guo SJ; Li Y; Bi LJ; Deng JY; Zhang XE; Tao SC
Sci Rep; 2017 Jul; 7(1):5860. PubMed ID: 28725053
[TBL] [Abstract][Full Text] [Related]
30. [GenoType MTBDR plus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis].
Rueda J; Realpe T; Mejía G; Zapata E; Robledo J
Biomedica; 2015; 35(4):541-8. PubMed ID: 26844443
[TBL] [Abstract][Full Text] [Related]
31. Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.
Grau T; Selchow P; Tigges M; Burri R; Gitzinger M; Böttger EC; Fussenegger M; Sander P
Antimicrob Agents Chemother; 2012 Feb; 56(2):1142-5. PubMed ID: 22106218
[TBL] [Abstract][Full Text] [Related]
32. Mutation in Eth A protein of Mycobacterium tuberculosis conferred drug tolerance against enthinoamide in Mycobacterium smegmatis mc
Anand PK; Kumar A; Saini A; Kaur J
Comput Biol Chem; 2022 Jun; 98():107677. PubMed ID: 35397466
[TBL] [Abstract][Full Text] [Related]
33. Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand.
Boonaiam S; Chaiprasert A; Prammananan T; Leechawengwongs M
Clin Microbiol Infect; 2010 Apr; 16(4):396-9. PubMed ID: 19486070
[TBL] [Abstract][Full Text] [Related]
34. Ethionamide biomimetic activation and an unprecedented mechanism for its conversion into active and non-active metabolites.
Laborde J; Deraeve C; Duhayon C; Pratviel G; Bernardes-Génisson V
Org Biomol Chem; 2016 Sep; 14(37):8848-8858. PubMed ID: 27714216
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
Costa-Gouveia J; Pancani E; Jouny S; Machelart A; Delorme V; Salzano G; Iantomasi R; Piveteau C; Queval CJ; Song OR; Flipo M; Deprez B; Saint-André JP; Hureaux J; Majlessi L; Willand N; Baulard A; Brodin P; Gref R
Sci Rep; 2017 Jul; 7(1):5390. PubMed ID: 28710351
[TBL] [Abstract][Full Text] [Related]
36. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
37. Antituberculosis drugs in children.
Schaaf HS; Garcia-Prats AJ; Donald PR
Clin Pharmacol Ther; 2015 Sep; 98(3):252-65. PubMed ID: 26095192
[TBL] [Abstract][Full Text] [Related]
38. Radiometric vs. agar proportion methods for assessing ethionamide resistance and its clinical effects in multidrug-resistant tuberculosis.
Cimen NO; Arslan Z; Saygi A; Ocak K; Babacan F; Kurutepe M
Int J Tuberc Lung Dis; 2009 Jul; 13(7):907-13. PubMed ID: 19555543
[TBL] [Abstract][Full Text] [Related]
39. Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
Vale N; Correia A; Silva S; Figueiredo P; Mäkilä E; Salonen J; Hirvonen J; Pedrosa J; Santos HA; Fraga A
Bioorg Med Chem Lett; 2017 Feb; 27(3):403-405. PubMed ID: 28057421
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of antituberculous drug resistance among Mycobacterium tuberculosis isolates recovered at the American University of Beirut Medical Center: 1996-1998 vs 1994-1995.
Araj GF; Itani LY; Kanj NA; Jamaleddine GW
J Med Liban; 2000; 48(1):18-22. PubMed ID: 10881438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
